HeartFlow is a medical technology company revolutionizing precision heart care.
There is no company in the world doing what we do—combining decades of human ingenuity and advanced technology in a completely novel way. We are passionate about transforming the diagnosis and management of coronary artery disease and continue to innovate, pushing into new frontiers and forging incredible partnerships along the way. Learn more about our story below.
Hear from our founders and customers around the world who are using our innovative technology as they tell the HeartFlow story and describe what makes our company and technology so transformational.
Began development of image-based modeling for coronary blood flow
Charles Taylor PhD: expert in computational fluid dynamics at Stanford University
Christopher Zarins MD: chair of vascular surgery at Stanford University
Founded HeartFlow in Silicon Valley, California
Awarded CE Mark
Commercially available in Europe
Received U.S. FDA de novo 510(k) clearance
Commercially available in the U.S.
Commercially available in Canada
Launched ADVANCE Registry to evaluate data from 5,000 patients
Commercially available in Japan
> 150 peer-reviewed publications
> 150 issued and allowed patents worldwide
NICE Guidance recommends HeartFlow
> 10,000 patients worldwide have received the HeartFlow Analysis
Announced collaboration with Siemens Healthineers
Innovation and Technology Payment Program Awarded by NHS England
Received reimbursement approval in Japan from MHLW
Launched PRECISE Randomized Clinical Trial
Named one of the World’s Most Innovative Companies by Fast Company
FDA Clearance Received for HeartFlow Planner
FORECAST trial results show increased treatment efficiency with HeartFlow Analysis
JAMA Network Open Publication Demonstrates the Coronary CT-HeartFlow Analysis Pathway is ‘Dominant’ Compared to Stress Testing in Cost-Effectiveness Analysis
NHS England and NHS Improvement mandate adoption of AI-powered HeartFlow Analysis to fight coronary heart disease
Completes Patient Enrollment in the PRECISE Trial